文献速递临床试验与 GCP

帕博利珠单抗联合化疗对比安慰剂联合化疗一线治疗转移性三阴性乳腺癌:KEYNOTE-355 三期随机对照试验

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
PubMed 文献 · Lancet · 2020-01-01

KEYNOTE-355 是一项在 29 国 209 中心开展的随机、安慰剂对照、双盲 3 期试验,847 例既往未治疗的局部复发不可手术或转移性三阴性乳腺癌患者按 2:1 随机接受帕博利珠单抗(200 mg 每 3 周)联合化疗或安慰剂联合化疗。主要终点为 PD-L1 CPS≥10、CPS≥1 和意向治疗人群的无进展生存期(PFS)与总生存期。

要点

  • 3-5 级治疗相关不良事件发生率两组相近(68% vs 67%),帕博利珠单抗组死亡 <1%,安慰剂组 0%。

核心结论

  • 在 PD-L1 CPS≥10 的转移性三阴性乳腺癌患者中,帕博利珠单抗联合化疗较安慰剂联合化疗显著且具有临床意义地改善无进展生存期。
  • 结果提示帕博利珠单抗联合标准化疗可作为转移性三阴性乳腺癌一线治疗的选择。

研究设计与样本

  • 随机、安慰剂对照、双盲 3 期试验,在 29 个国家 209 个中心开展。
  • 847 例既往未治疗的局部复发不可手术或转移性三阴性乳腺癌患者按 2:1 随机分配至帕博利珠单抗联合化疗组(566 例)或安慰剂联合化疗组(281 例)。
  • 随机分层因素包括研究化疗类型(紫杉类或吉西他滨-卡铂)、基线 PD-L1 表达(CPS≥1 或 <1)和新辅助/辅助阶段是否用过同类化疗。
  • 双主要终点为 PD-L1 CPS≥10、CPS≥1 和意向治疗人群的 PFS 与总生存期;本次分析为 PFS 的确定性评估,总生存期随访继续。

主要发现

  • 帕博利珠单抗的治疗效应随 PD-L1 富集程度增加而增强。
  • 3-5 级治疗相关不良事件发生率:帕博利珠单抗联合化疗组 68%,安慰剂联合化疗组 67%;治疗相关死亡分别为 <1% 和 0%。

关键数值与推荐

  • 入组要求:年龄≥18 岁、中心确认的三阴性乳腺癌、至少一个可测量病灶、ECOG 体能状态评分 0 或 1、器官功能充分。

临床怎么用

  • 对于 PD-L1 CPS≥10 的既往未治疗局部复发不可手术或转移性三阴性乳腺癌患者,可考虑帕博利珠单抗联合化疗作为一线治疗。
  • 治疗前应通过中心实验室免疫组化检测肿瘤 PD-L1 表达状态(CPS),以筛选优势人群。
  • 帕博利珠单抗联合化疗的 3-5 级治疗相关不良事件发生率与安慰剂联合化疗相近,但需监测治疗相关死亡(<1%)。

局限性

  • 本次分析为 PFS 的确定性评估,总生存期随访仍在进行中,总生存数据尚未报告。
  • 意向治疗人群的 PFS 未进行正式统计检验,不能据此得出该人群获益的确定性结论。
  • CPS≥1 人群未达到预设统计学显著,该人群的获益证据不充分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the addition of pembrolizumab would enhance the antitumour activity of chemotherapy in patients with metastatic triple-negative breast cancer. METHODS: In this randomised, placebo-controlled, double-blind, phase 3 trial, done in 209 sites in 29 countries, we randomly assigned patients 2:1 with untreated locally recurrent inoperable or metastatic triple-negative breast cancer using a block method (block size of six) and an interactive voice-response system with integrated web-response to pembrolizumab (200 mg) every 3 weeks plus chemotherapy (nab-paclitaxel; paclitaxel; or gemcitabine plus carboplatin) or placebo plus chemotherapy. Randomisation was stratified by type of on-study chemotherapy (taxane or gemcitabine-carboplatin), PD-L1 expression at baseline (combined positive score [CPS] ≥1 or <1), and previous treatment with the same class of chemotherapy in the neoadjuvant or adjuvant setting (yes or no). Eligibility criteria included age at least 18 years, centrally confirmed triple-negative breast cancer; at least one measurable lesion; provision of a newly obtained tumour sample for determination of triple-negative breast cancer status and PD-L1 status by immunohistochemistry at a central laboratory; an Eastern Cooperative Oncology Group performance status score 0 or 1; and adequate organ function. The sponsor, investigators, other study site staff (except for the unmasked pharmacist), and patients were masked to pembrolizumab versus saline placebo administration. In addition, the sponsor, the investigators, other study site staff, and patients were masked to patient-level tumour PD-L1 biomarker results. Dual primary efficacy endpoints were progression-free survival and overall survival assessed in the PD-L1 CPS of 10 or more, CPS of 1 or more, and intention-to-treat populations. The definitive assessment of progression-free survival was done at this interim analysis; follow-up to assess overall survival is continuing. For progression-free survival, a hierarchical testing strategy was used, such that testing was done first in patients with CPS of 10 or more (prespecified statistical criterion was α=0·00411 at this interim analysis), then in patients with CPS of 1 or more (α=0·00111 at this interim analysis, with partial alpha from progression-free survival in patients with CPS of 10 or more passed over), and finally in the intention-to-treat population (α=0·00111 at this interim analysis). This study is registered with ClinicalTrials.gov, NCT02819518, and is ongoing. FINDINGS: Between Jan 9, 2017, and June 12, 2018, of 1372 patients screened, 847 were randomly assigned to treatment, with 566 patients in the pembrolizumab-chemotherapy group and 281 patients in the placebo-chemotherapy group. At the second interim analysis (data cutoff, Dec 11, 2019), median follow-up was 25·9 months (IQR 22·8-29·9) in the pembrolizumab-chemotherapy group and 26·3 months (22·7-29·7) in the placebo-chemotherapy group. Among patients with CPS of 10 or more, median progression-free survival was 9·7 months with pembrolizumab-chemotherapy and 5·6 months with placebo-chemotherapy (hazard ratio [HR] for progression or death, 0·65, 95% CI 0·49-0·86; one-sided p=0·0012 [primary objective met]). Median progression-free survival was 7·6 and 5·6 months (HR, 0·74, 0·61-0·90; one-sided p=0·0014 [not significant]) among patients with CPS of 1 or more and 7·5 and 5·6 months (HR, 0·82, 0·69-0·97 [not tested]) among the intention-to-treat population. The pembrolizumab treatment effect increased with PD-L1 enrichment. Grade 3-5 treatment-related adverse event rates were 68% in the pembrolizumab-chemotherapy group and 67% in the placebo-chemotherapy group, including death in <1% in the pembrolizumab-chemotherapy group and 0% in the placebo-chemotherapy group. INTERPRETATION: Pembrolizumab-chemotherapy showed a significant and clinically meaningful improvement in progression-free survival versus placebo-chemotherapy among patients with metastatic triple-negative breast cancer with CPS of 10 or more. These findings suggest a role for the addition of pembrolizumab to standard chemotherapy for the first-line treatment of metastatic triple-negative breast cancer. FUNDING: Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020. PMID: 33278935. doi:10.1016/S0140-6736(20)32531-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。